Athira Pharma to Present at H.C. Wainwright & Co. Global Life Sciences Conference
Athira Pharma (NASDAQ: ATHA) will present a corporate overview at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Athira Pharma (NASDAQ: ATHA) will present a corporate overview at the H.C. Wainwright & Co. Global Life Sciences Conference. Leen Kawas, Ph.D., President and CEO, will lead the pre-recorded presentation available at 7:00 am ET on March 9, 2021. The presentation can be accessed on-demand through the Athira website, with an archived replay available for 90 days post-event. Athira focuses on developing small molecules to restore neuronal health, targeting Alzheimer’s and Parkinson’s dementia with its lead candidate, ATH-1017.
Details
News Market Reaction – ATHA
The recorded move for ATHA in the trading session of this news was -2.57%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will present a corporate overview during the H.C. Wainwright & Co. Global Life Sciences Conference. A pre-recorded presentation will be available for on-demand viewing beginning at 7:00 am ET on Tuesday, March 9, 2021.
A webcast of the presentation will also be available on the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay of the webcast will be available for approximately 90 days following the event.
About Athira Pharma, Inc.
Athira, headquartered in Seattle, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.
Investor & Media Contact:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.